Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.Mehul Gupta, Daniel Yick Chin Heng, Connor Wells et al.|Journal of Clinical Oncology|2024Cited by 0
Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.Hyejee Ohm, Naveen S. Basappa, Vincent Castonguay et al.|Journal of Clinical Oncology|2024Cited by 0